Invest in domestic API manufacturing capacity for essential medicines
Expand biomanufacturing capabilities for biologics and biosimilars
Develop CDMO (contract development and manufacturing) services for global clients
Pursue regulatory harmonization with FDA to reduce market access friction
Build strategic stockpiles of critical pharmaceutical ingredients
CUSMA extended data protection periods for biologics and enhanced IP provisions that generally benefit US-headquartered pharmaceutical firms. Canadian generic manufacturers face longer market exclusivity periods before they can launch competing products. The agreement's pharmaceutical provisions reflect US industry priorities, creating structural advantages for innovator companies over Canadian generics.
Canada imports approximately 68% of active pharmaceutical ingredients, primarily from India and China. The COVID-19 pandemic exposed critical vulnerabilities in API and finished dose supply chains. Domestic vaccine manufacturing capacity, while expanding, remains insufficient for pandemic-scale production.
Canada's pharmaceutical sector is dominated by multinational subsidiaries and a strong generics segment. Apotex and other Canadian generics compete globally but face margin pressure from Indian manufacturers. The biomanufacturing segment is growing, with significant government investment in domestic biologics capacity since 2021.
Post-pandemic investment in domestic biomanufacturing creates growth opportunities. The sector benefits from lower tariff exposure than goods-producing industries but faces IP and regulatory challenges under CUSMA. Cell and gene therapy manufacturing represents a high-value frontier where Canada is establishing competitive positions.
Key trade partners for the pharmaceutical manufacturing industry
Automotive Manufacturing
Aerospace Manufacturing
Steel & Aluminum Production
Plastics & Rubber Manufacturing
Industrial Machinery & Equipment
Electronics Manufacturing
Industry disruption demands strategic response. Our team helps organizations adapt to shifting trade dynamics.
Strategic analysis on trade policy, geopolitical disruption, and competitive intelligence. Published when it matters, not on a schedule.